{"product_id":"srts-vrio-analysis","title":"Sensus Healthcare, Inc. (SRTS): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eWhat truly sets Sensus Healthcare, Inc. (SRTS) apart in the marketplace? This VRIO analysis cuts straight to the core, dissecting its key resources against the crucial tests of Value, Rarity, Inimitability, and Organization to pinpoint its sources of sustainable competitive advantage. Dive in now to see the distilled findings on whether Sensus Healthcare, Inc. (SRTS) is built for long-term market dominance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSensus Healthcare, Inc. (SRTS) - VRIO Analysis: 1. Proprietary Superficial Radiotherapy (SRT) Technology\n\u003c\/h2\u003e\n\u003cp\u003eYou're looking at the core engine of Sensus Healthcare, the proprietary Superficial Radiotherapy (SRT) technology, which underpins their entire market proposition. The recent validation from CMS establishing dedicated CPT® codes for SRT in the third quarter of 2025 is a massive near-term catalyst, directly boosting the \u003cstrong\u003eValue\u003c\/strong\u003e of this asset by improving reimbursement certainty for your customers.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math: for the nine months ending September 30, 2025, the company posted revenues of \u003cstrong\u003e$22.5 million\u003c\/strong\u003e, and they exited the quarter with \u003cstrong\u003e$24.5 million\u003c\/strong\u003e in cash, showing the financial structure supporting this tech. Still, the TTM revenue was \u003cstrong\u003e$35.61 million\u003c\/strong\u003e, indicating the technology's adoption is still scaling up despite the clinical validation.\u003c\/p\u003e\n\u003cp\u003eThis technology is what separates Sensus Healthcare from the pack, and frankly, it’s why we watch them. It’s not just a product; it’s a protected, clinical niche.\u003c\/p\u003e\n\u003cp\u003eThe VRIO assessment for this core resource looks strong, suggesting a durable competitive position:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eCompetitive Implication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eEnables cost-effective, non-invasive NMSC treatment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eSpecialized low-energy x-ray tech with IG-SRT application.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability (I)\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eProtected by patents, including workflow management (Patent No. 11,894,123 B2).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eMarketing the SRT-100™ line and managing Fair Deal Agreements (FDAs).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eStrong moat from IP and regulatory\/clinical positioning.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe evidence supporting this structure is clear, especially when you look at recent operational metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eValue is being realized: FDA treatment volume grew \u003cstrong\u003e20%\u003c\/strong\u003e sequentially in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eRarity is evident: Only \u003cstrong\u003e56\u003c\/strong\u003e units were sold year-to-date through Q3 2025, showing low volume but high specialization.\u003c\/li\u003e\n\u003cli\u003eImitability defense: The core technology is protected by patents covering systems like the SRT-100 Vision, which fuses ultrasound and optical imaging data.\u003c\/li\u003e\n\u003cli\u003eOrganization is active: They shipped \u003cstrong\u003e16\u003c\/strong\u003e SRT systems in Q3 2025 alone, showing they can convert interest into placements.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIf onboarding takes 14+ days, churn risk rises, but the new CMS codes should help accelerate the sales cycle defintely.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSensus Healthcare, Inc. (SRTS) - VRIO Analysis: 2. U.S. Patent No. 11,894,123 B2 (Workflow Management System)\n\u003c\/h2\u003e\n\u003cp\u003eU.S. Patent No. 11,894,123 B2, titled “Radiotherapy Mobile and Wireless Device Workflow Management System,” was issued on February 8, 2024. This patent covers 33 individual claims.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePatent Component\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003eScope Detail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore Technology\u003c\/td\u003e\n\u003ctd\u003eSystems and methods for treating a patient\u003c\/td\u003e\n\u003ctd\u003eCombines high-frequency ultrasound and optical imaging data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApplication\u003c\/td\u003e\n\u003ctd\u003eTreatment-planning system\u003c\/td\u003e\n\u003ctd\u003eEnables 3D image guidance for treatment suggestion and plan creation for the SRT-100 Vision\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkflow Management\u003c\/td\u003e\n\u003ctd\u003eAncillary System Functions\u003c\/td\u003e\n\u003ctd\u003eCovers scheduling patient appointments and detecting\/communicating medical equipment status to service engineers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe SRT-100 Vision (IG-SRT) system is noted as increasingly important to Sensus Healthcare.\u003c\/p\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eProtects the integrated workflow of the SRT-100 Vision, fusing ultrasound and optical imaging for treatment planning. This proprietary technology is essential for the SRT-100 Vision product line.\u003c\/p\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eYes. This specific, detailed patent covering the fusion of imaging and treatment delivery is rare. The patent covers the specific integration of imaging data for planning within the radiotherapy system.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eVery high. Competitors cannot legally use this specific planning system without licensing. The patent protection ensures exclusivity over the described methods and systems.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eYes. This patent directly supports the high-value SRT-100 Vision product line, which is central to the company's strategy, including the introduction of a recurring revenue model for the system in Q4 2023. The company ended 2023 with $23.1 million in cash and no debt, positioning it to support the commercialization of patented technology.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe recurring revenue model for the SRT-100 Vision (IG-SRT), supported by this IP, saw 15 agreements signed by the end of Q2 2024 and an expectation to exceed 50 by the end of 2024.\u003c\/li\u003e\n\u003cli\u003eFull Year 2023 Revenue was $24.4 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained. Patent protection is the strongest barrier to imitation. The 33 claims provide a broad legal shield around the workflow management and imaging fusion aspects of the SRT-100 Vision.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSensus Healthcare, Inc. (SRTS) - VRIO Analysis: 3. CMS Dedicated CPT® Coding Validation\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides compelling economics and reimbursement certainty for treating non-melanoma skin cancer, directly driving adoption.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eReimbursement per fraction increased by \u003cstrong\u003eover 300%\u003c\/strong\u003e compared to existing treatment\/fractionation codes.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Revenues were \u003cstrong\u003e$6.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes. Securing dedicated CPT codes from CMS is a massive, hard-won regulatory achievement.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCMS published a distinct set of treatment codes specific to the use of superficial radiotherapy (SRT and IG-SRT) for non-melanoma skin cancer (NMSC).\u003c\/li\u003e\n\u003cli\u003eThis followed the American Medical Association's establishment of dedicated CPT codes for superficial radiotherapy earlier in the year.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Very high. This is a regulatory status, not a product; competitors cannot easily replicate this established code.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCMS validation included inclusion in the \u003cstrong\u003e2026 Physician Fee Schedule\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe dedicated CPT codes reflect CMS' acknowledgement of SRT as a \u003cstrong\u003estandalone treatment modality\u003c\/strong\u003e for NMSC.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. Management is actively capitalizing on this, noting Q3 FDA treatment volume increased 20% sequentially.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 Sequential FDA Treatment Volume Increase\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive Fair Deal Agreement (FDA) Sites (End of Q3)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e21\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePending FDA Sites (End of Q3)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSRT Systems Shipped (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e16\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and No Debt (End of Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$24.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This regulatory\/reimbursement status is a durable advantage over non-coded alternatives.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSRTS shares traded up \u003cstrong\u003e15.16%\u003c\/strong\u003e (to \u003cstrong\u003e$3.57\u003c\/strong\u003e) on the day of the CMS announcement.\u003c\/li\u003e\n\u003cli\u003eThe new codes narrow the gap between office-based reimbursement and hospital outpatient rates.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSensus Healthcare, Inc. (SRTS) - VRIO Analysis: 4. Debt-Free Balance Sheet and Cash Position\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides financial flexibility and resilience; they exited Q3 2025 with \u003cstrong\u003e$24.5 million\u003c\/strong\u003e in cash and no debt.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many small medical device firms carry debt; being debt-free is uncommon but achievable.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can achieve this by selling assets or managing cash flow well, but it takes time.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. This clean balance sheet allows for focused investment in R\u0026amp;D and commercial expansion.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s a strong position now, but cash can be spent, and debt can be taken on.\u003c\/p\u003e\n\n\u003cp\u003eThe current liquidity position is a significant factor in operational planning, especially given the recent regulatory developments and inventory levels.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2025\u003c\/th\u003e\n\u003cth\u003eQ2 2025\u003c\/th\u003e\n\u003cth\u003eFY 2024 End\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$24.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$22.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$22.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe balance sheet strength supports ongoing operations and strategic initiatives, such as maintaining inventory levels to meet anticipated demand acceleration.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eRevenues for Q3 2025 were \u003cstrong\u003e$6.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Loss for Q3 2025 was \u003cstrong\u003e$0.9 million\u003c\/strong\u003e, or \u003cstrong\u003e$0.06\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003cli\u003eGross Margin compressed to \u003cstrong\u003e39.1%\u003c\/strong\u003e in Q3 2025, compared to \u003cstrong\u003e59.1%\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003cli\u003eSRT systems shipped in Q3 2025 totaled \u003cstrong\u003e16\u003c\/strong\u003e units.\u003c\/li\u003e\n\u003cli\u003eFinished goods inventory was approximately \u003cstrong\u003e$13 million\u003c\/strong\u003e as of Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSensus Healthcare, Inc. (SRTS) - VRIO Analysis: 5. Fair Deal Agreement (FDA) Program\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Creates a stream of recurring revenue based on treatment volume, rather than just upfront system sales.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While service contracts exist, this specific program structure for SRT systems is unique to Sensus.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can design similar recurring revenue models, but the established customer base is sticky.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The program is clearly a focus, with treatment volume growth cited in earnings reports.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s a strong revenue driver, but the model itself is imitable over time.\u003c\/p\u003e\n\u003cp\u003eThe FDA program is designed to generate recurring revenue streams, which partially offset a decrease in upfront system sales revenue in the third quarter of 2025. Revenue recognized from the new placement program under the Fair Deal Agreement was noted as a factor in the Q3 2025 results, despite overall revenues declining to $6.9 million from $8.8 million in Q3 2024.\u003c\/p\u003e\n\u003cp\u003eThe operational focus on the program is evidenced by the growth in utilization metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFDA treatment volume increased 20% over the second quarter of 2025.\u003c\/li\u003e\n\u003cli\u003eFDA treatment volume increased 52% compared with the first quarter of 2025.\u003c\/li\u003e\n\u003cli\u003eAs of the end of the third quarter of 2025, 21 FDA sites were active with 11 pending to go live.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe following table summarizes key financial and program metrics around the FDA initiative:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Data\u003c\/th\u003e\n\u003cth\u003eHistorical Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$8.8 million in Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA Treatment Volume Growth (QoQ)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e20%\u003c\/strong\u003e increase over Q2 2025\u003c\/td\u003e\n\u003ctd\u003e27% sequential increase in FDA treatment volume in Q2 2025 over Q1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive\/Pending FDA Sites\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e21\u003c\/strong\u003e active sites; \u003cstrong\u003e11\u003c\/strong\u003e pending\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e22\u003c\/strong\u003e Fair Deal Agreements signed since March 2024 as of Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (End of Period)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$24.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$22.6 million as of end of Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe cost associated with the new placement program was cited as a factor contributing to the gross margin compression in Q3 2025 compared to Q3 2024 (\u003cstrong\u003e39.1%\u003c\/strong\u003e vs \u003cstrong\u003e59.1%\u003c\/strong\u003e).\u003c\/p\u003e\n\u003cp\u003eThe established customer base under the FDA model is noted as being sticky, contributing to the ongoing utilization growth despite lower system unit sales (e.g., 16 systems shipped in Q3 2025 vs. 27 in Q3 2024).\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSensus Healthcare, Inc. (SRTS) - VRIO Analysis: 6. Established Distribution Partnership with ROS\n\u003c\/h2\u003e\n\u003cp\u003eValue: Provides a direct channel to hospital-based radiation oncology departments, a key segment for broader adoption beyond dermatology.\u003c\/p\u003e\n\u003cp\u003eRarity: Low. Distribution deals are common in med-tech, though the specific partner matters.\u003c\/p\u003e\n\u003cp\u003eImitability: Moderate. Competitors can sign similar deals, but the existing relationship has built-in trust.\u003c\/p\u003e\n\u003cp\u003eOrganization: Yes. The engagement with Radiology Oncology Systems (ROS) shows a strategy to move into new care settings.\u003c\/p\u003e\n\u003cp\u003eCompetitive Advantage: Temporary. The specific partner can be poached or replaced by a competitor’s better offer.\u003c\/p\u003e\n\u003cp\u003eThe strategic agreement with Radiology Oncology Systems (ROS) targets U.S. market expansion into hospital-based radiation oncology departments and freestanding oncology centers nationwide for the SRT-100™ and SRT-100 Vision™ systems.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eROS Experience\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNearly three decades\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAcross radiation oncology.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eROS Geographic Reach\u003c\/td\u003e\n\u003ctd\u003eAll \u003cstrong\u003e50 states\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eLeveraged for U.S. distribution.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Initial Orders\u003c\/td\u003e\n\u003ctd\u003eAs early as \u003cstrong\u003eQ4 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eUnder the ROS agreement.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSRT Systems Shipped\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e19\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSRT Systems Shipped\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e21\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSRT Systems Shipped (Record)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e39\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ4 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Installed Base (Approx.)\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e880 systems\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of Q2 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOperational metrics leading up to and immediately following the partnership announcement include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRevenue for Q2 2025 was \u003cstrong\u003e$7.3 million\u003c\/strong\u003e, compared with \u003cstrong\u003e$9.2 million\u003c\/strong\u003e in Q2 2024.\u003c\/li\u003e\n\u003cli\u003eRevenue for Q1 2025 was \u003cstrong\u003e$8.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet loss for Q2 2025 was \u003cstrong\u003e$1.0 million\u003c\/strong\u003e, or \u003cstrong\u003e$0.06 per share\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet income for Q2 2024 was \u003cstrong\u003e$1.6 million\u003c\/strong\u003e, or \u003cstrong\u003e$0.10 per diluted share\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFDA treatment volume increased \u003cstrong\u003e27%\u003c\/strong\u003e sequentially from Q1 to Q2 2025.\u003c\/li\u003e\n\u003cli\u003eThe company ended Q2 2025 with \u003cstrong\u003e$22.2 million\u003c\/strong\u003e in cash and \u003cstrong\u003eno debt\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSensus Healthcare, Inc. (SRTS) - VRIO Analysis: 7. Commercial SRT Product Portfolio (SRT-100 Family)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Offers clinicians a proven, multi-generational suite of devices (SRT-100, +) for treating skin conditions. The market for non-melanoma skin cancer treatments is enormous, with an estimated one in five Americans developing skin cancer during their lifetime, representing some 70 million people globally, and more than 1.2 million people developing non-melanoma skin cancer annually.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Low. Having multiple product versions is standard for established device makers.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Low. Competitors can develop similar devices, though they lack the installed base and clinical history. The company announced the installation of its 500th unit on April 5, 2021.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Yes. The company actively sells and services this installed base, which supports the recurring revenue model. The company expects to have more than 50 IG-SRT Systems signed under the Fair Deal Agreement recurring-revenue program by the end of the year (2024).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: None. This is a necessary baseline capability in this industry.\u003c\/p\u003e\n\u003cp\u003eThe commercial performance of the SRT product portfolio demonstrates recent growth:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2024\u003c\/th\u003e\n\u003cth\u003eQ3 2023\u003c\/th\u003e\n\u003cth\u003eQ2 2024\u003c\/th\u003e\n\u003cth\u003eQ2 2023\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSystem Shipments (Total)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e27 systems\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11 systems\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23 systems\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13 systems\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income (Loss)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e($1.5 million)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e($0.4 million)\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAdditional relevant statistics regarding the product portfolio and usage include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company entered into Fair Deal Agreements for seven SRT-100 Vision (IG-SRT) units in Q3 2024, bringing the total to 22 units since the program's introduction in March 2024.\u003c\/li\u003e\n\u003cli\u003eIn Q2 2024, three SRT-100 units were shipped to Asia.\u003c\/li\u003e\n\u003cli\u003eAs of Q3 2017, 70 units were being used to treat keloid scars in addition to skin cancer.\u003c\/li\u003e\n\u003cli\u003eThe company exited Q3 2024 with $22.6 million in cash and cash equivalents and no debt.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSensus Healthcare, Inc. (SRTS) - VRIO Analysis: 8. Pipeline of Next-Generation Devices (Ultrasound\/TDI)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Signals future growth potential and diversification beyond the core SRT platform into detection and drug delivery.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Developing new products is expected, but the specific combination (handheld ultrasound, TDI) is niche.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. The R\u0026amp;D process is hard to copy, but the final product can be reverse-engineered once launched.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. Showcasing these pre-commercial products at conferences demonstrates commitment to innovation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s an opportunity, but only becomes a sustained advantage upon successful commercialization.\u003c\/p\u003e\n\u003cp\u003eThe commitment to developing these next-generation assets is reflected in the company's investment in Research and Development.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePeriod\u003c\/th\u003e\n\u003cth\u003eResearch and Development Expense\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFirst Half 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFirst Half 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company showcased several pre-commercial products at the 2025 American Academy of Dermatology (AAD) Annual Meeting, including:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSensus' new prototype handheld ultrasound device, designed to help clinicians identify skin lesions.\u003c\/li\u003e\n\u003cli\u003eIts work-in-process TransDermal Infusion (TDI) product with Sentinel™ IT Solutions capabilities.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe increase in Research and Development expense for the first quarter of 2025 compared to the prior-year quarter was primarily due to significant lobbying costs related to billing code reimbursement, increased headcount, and product development cost related to next-generation systems.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ1 2025 Research and development expense: \u003cstrong\u003e$2.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ1 2024 Research and development expense: \u003cstrong\u003e$0.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFirst half 2025 Research and development expense: \u003cstrong\u003e$4.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFirst half 2024 Research and development expense: \u003cstrong\u003e$1.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe company reported a net loss of \u003cstrong\u003e$2.6 million\u003c\/strong\u003e for the first quarter of 2025, while maintaining cash and cash equivalents of \u003cstrong\u003e$22.2 million\u003c\/strong\u003e as of June 30, 2025, with no outstanding borrowings under its revolving line of credit.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSensus Healthcare, Inc. (SRTS) - VRIO Analysis: 9. Clinical Credibility in Keloid and NMSC Treatment\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Builds trust with dermatologists and oncologists, supported by published studies demonstrating efficacy.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eImage-guided SRT (IGSRT) review showed an overall control rate of 99.3% for keratinocytic carcinomas at last follow-up.\u003c\/li\u003e\n\u003cli\u003eControl rate of 99.3% observed for tumors with at least 1 year of follow-up ($n = 1639$).\u003c\/li\u003e\n\u003cli\u003eKeloid recurrence rates with surgery alone can be as high as 45 to 100%.\u003c\/li\u003e\n\u003cli\u003eA study in Taiwan demonstrated no recurrence in 12 patients with 16 keloids followed for over six months after combining surgical excision with SRT.\u003c\/li\u003e\n\u003cli\u003eCenters for Medicare \u0026amp; Medicaid Services (CMS) established coding validating superficial radiotherapy (SRT) for treating non-melanoma skin cancer.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Moderate. Clinical validation is required, but deep expertise in a specific niche is less common.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe SRT-100™ received FDA clearance to treat Keloids in 2013.\u003c\/li\u003e\n\u003cli\u003eIn a chart review of 96 excised keloids followed for at least 1 year, 56% experienced hyperpigmentation.\u003c\/li\u003e\n\u003cli\u003ePersistent hyperpigmentation occurred in less than 5% of patients in that review.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: High. Clinical data and physician trust take years to build and are hard for a newcomer to replicate quickly.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eClinical data supporting efficacy requires follow-up periods of 1 year or more.\u003c\/li\u003e\n\u003cli\u003eThe company's Fair Deal Agreement (FDA) treatment volume increased 20% over the second quarter in Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Yes. The company uses clinical studies and KOL feedback to guide development and marketing efforts.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company attended the American Society for Radiation Oncology (ASTRO) 66th annual meeting.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained. Deep clinical acceptance in a specific indication is a powerful, slow-to-erode asset.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eVRIO Analysis Summary:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eAttribute\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eSupporting Data\/Metric\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eBuilds trust\u003c\/td\u003e\n\u003ctd\u003eNMSC IGSRT control rate: 99.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eFDA Clearance for Keloids: 2013\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eTime to build trust\/data (e.g., 1 year follow-up cited)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eCMS established coding for SRT\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eDraft 13-Week Cash Flow Projection Incorporating Q3 Cash Balance:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eWeek 1\u003c\/td\u003e\n\u003ctd\u003eWeek 2\u003c\/td\u003e\n\u003ctd\u003eWeek 3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeginning Cash Balance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$24,500,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$24,450,000\u003c\/td\u003e\n\u003ctd\u003e$24,400,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Receipts (Inflows)\u003c\/td\u003e\n\u003ctd\u003e$6,900,000\u003c\/td\u003e\n\u003ctd\u003e$5,500,000\u003c\/td\u003e\n\u003ctd\u003e$7,100,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Disbursements (Outflows)\u003c\/td\u003e\n\u003ctd\u003e$6,950,000\u003c\/td\u003e\n\u003ctd\u003e$5,550,000\u003c\/td\u003e\n\u003ctd\u003e$7,050,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnding Cash Balance\u003c\/td\u003e\n\u003ctd\u003e$24,450,000\u003c\/td\u003e\n\u003ctd\u003e$24,400,000\u003c\/td\u003e\n\u003ctd\u003e$24,450,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516255789205,"sku":"srts-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/srts-vrio-analysis.png?v=1740214237","url":"https:\/\/dcf-model.com\/pt\/products\/srts-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}